L. Jentzsch

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

E. Hoster, L. Bullinger, A. Mackensen, 2022, Journal for ImmunoTherapy of Cancer.

CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.

E. Hoster, G. Salles, A. Mackensen, 2021, Blood.

Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies

M. Subklewe, W. Bethge, C. Berger, 2020 .